US Patent

US9273077 — Phosphorus derivatives as kinase inhibitors

Method of Use · Assigned to Ariad Pharmaceuticals Inc · Expires 2029-05-21 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds of a specific formula and their use as protein kinase inhibitors.

USPTO Abstract

The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use as protein kinase inhibitors.

Drugs covered by this patent

Alunbrig (brigatinib) · Takeda

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2837`	—	Alunbrig
`U-2837`	—	Alunbrig
`U-2837`	—	Alunbrig

Patent Metadata

Patent number: US9273077
Jurisdiction: US
Classification: Method of Use
Expires: 2029-05-21
Drug substance claim: No
Drug product claim: No
Assignee: Ariad Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.